Table 3.
1 | SERS | Saliva. Sjögren's syndrome (SjS) | 2020 [Moisoiu 2020] | 96.5% |
---|---|---|---|---|
2 | ATR-IR | Periodontal Diseases | 2020 [Beyer-Hans et al. 2020] | _ |
3 | ATR-FTIR | Bio fluids including saliva; Review, clinical applications | 2020 [Naseer et al. 2020] | _ |
4 | Raman | Amyotrophic Lateral Sclerosis (ALS) diagnosis | 2020 [Carlomagno et al. 2020] | _ |
5 | SERS | Periodontitis, Sialic Acid (SA) | 2019 [Hernández-Cedillo et al. 2019] | 69.6% |
6 | SERS | To evaluate the activity of urease in saliva. Dental caries; helicobacter pylori infection | 2019 [Hu et al. 2019] | L.O.D: 2.35 μg/ml |
7 | SERS |
biomarkers of bronchial inflammation in the saliva of children with asthma |
2019 [Zamora-Mendoza et al. 2019] | 85% |
8 | ATR-FTIR | Chronic kidney disease | 2019 [Rodrigues et al. 2019a, b] | 92.8% |
9 | FTIR | Burning Mouth Syndrome | 2019 [Rodrigues et al. 2019a, b] | _ |
10 | FTIR | Neonatal sepsis using saliva | 2019 [Yunanto et al. 2019] | _ |
11 | ATR-FTIR | Multiple dental caries | 2018 [Seredin et al. 2018] | _ |
12 | Plasmonics | Hepatitis B | 2017 [Riedel et al. 2017] | _ |
13 | IR | Saliva in healthy, chronic, and aggressive periodontitis | 2017 [Saranya 2017] | _ |
14 | Plasmonics | Hepatitis B | 2016 [Riedel et al. 2016] | _ |
15 | FTIR | Differentiation of chronic and aggressive Periodontitis | 2016 [Simsek Ozek et al. 2016] | 82% |
16 | ICP OES & ICP MS | Periodontal diseases. | 2016 [Herman et al. 2016] | L.O.D: 0.007 μg/l for Pb and 0.21 μg/l for Fe |
17 | Raman | Myocardial Infarction. Saliva spectroscopy; Multivariate analysis | 2015 [Cao et al. 2015] | 80.04% |
18 | FTIR | Saliva proteomic components in psoriatic and diabetic patients | 2015 [Bottoni et al. 2015] | _ |
19 | Fluorescence | Lithium in Bipolar disorder | 2011 [Kim et al. 2011] | _ |
20 | SPR | Mucin, Gingivitis, Periodontitis | 2007 [Fernández-González et al. 2007] | _ |